We identify hereby a novel mechanism of tumor-induced systemic T-cell dysfunction based on the activity of tumor-derived ARG1+ EVs, that may also apply to other arginase-expressing tumor types and may have significant clinical implications for T-cell immunotherapy approaches. Here, ARG1 is linked to neoplasm.